Art

J-GLOBAL ID：200902112358498153   Reference number：00A0108511

Infliximab(chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial.

Author (9)： MAINI R (Imperial Coll. School of Medicine at Charing Cross Hospital, London, GBR) ,  ST CLAIR E W (Duke Univ., North Carolina, USA) ,  BREEDVELD F (Univ. Leiden, Leiden, NLD) ,  FURST D (Virginia Mason Res. Center, Washington, USA) ,  KALDEN J (Inst. Clinical Immunological and Rheumatology, Erlangen, DEU) ,  WEISMAN M (Univ. California San Diego, California, USA) ,  SMOLEN J (Univ. Vienna, AUT) ,  EMERY P (Univ. Leeds, GBR) ,  LIPSKY P (Univ. Texas Southwestern Medical Center, Texas, USA)
Material： Lancet
Volume： 354  Issue： 9194  Page： 1932-1939  Publication year： Dec. 04, 1999 
JST Material Number： B0673A  ISSN： 0140-6736  CODEN： LANCA  Document type： Article
Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Terms in the title (1)： Infliximab